ClinicalTrials.gg

Program

KIF18A Inhibitor ATX-295

Also written as “ATX-295” and “ATX-295 and bevacizumab (or biosimilar)”.

Its studies are mostly in Ovarian Neoplasms, led by Accent Therapeutics.

Furthest: phase 2, since Jan 18, 20251 company-led study, 1 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Accent Therapeutics11 open or runningphase 2since Jan 18, 2025Jan 18, 2025Apr 30, 2027phase 2 · NCT06799065

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2025First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT06799065 · 218 planned · United States

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT06799065

TargetBeta

KIF18A →read by rule
“An orally bioavailable inhibitor of the human kinesin-like protein KIF18A, ”NCIt, by rule

Other programs on KIF18A

ProgramCompanyFurthest phaseStudies
KIF18A Inhibitor MEN2501ruleMenarini Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06799065Ovarian Neoplasms · United States2RecruitingApr 30, 2027218

How it is read

Names in the registry

  • “ATX-295”, 1 entry
  • “ATX-295 and bevacizumab (or biosimilar)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.